Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib Study in Indian Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient of either gender and ≥18 years of age~2. Patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, who have progressed on or after EGFR TKI therapy by an independent clinical judgment of treating physician based on locally approved prescribing information~3. Each patient must sign an informed consent form (ICF)~Exclusion Criteria:~1. Patient with either the history of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug.~2. Pregnant and/or lactating women~3. Patients participating in any current or future interventional trial will not be enrolled in the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Single (Type: EXPERIMENTAL): Single arm

Based on this trial design, predict the completion outcome and termination type (if applicable).